非小细胞肺癌EGFR突变的分子影像学在体检测

发布时间：2018-07-04 22:04

本文选题：肺肿瘤 + 表皮生长因子受体　；参考：《中国肺癌杂志》2017年06期

【摘要】：靶向药物表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)改变了非小细胞肺癌的治疗格局,研究表明只有EGFR敏感突变人群能从中获益。EGFR突变检测的主流方法是针对EGFR的DNA序列进行分析,标本可以是手术或穿刺获取的肺癌组织、胸水肿瘤细胞、循环肿瘤细胞、外周血游离DNA,其最大的缺点是无法分析EGFR突变的异质性。针对EGFR在蛋白质水平进行突变检测分析的技术尚不成熟,但随着分子影像学的发展,基于正电子发射型计算机断层显像(positron emission computed tomography,PET)-计算机断层扫描(computed tomography,CT)的靶向EGFR分子探针的研发,使得在体检测肺癌组织的EGFR突变状态成为了可能,而且可以检测EGFR突变的异质性。本文综述了目前靶向EGFR突变的分子探针的研究结果及进展。
[Abstract]:EGFR-TKI, an inhibitor of epidermal growth factor receptor tyrosine kinase (epidermal growth factor receptor tyrosine kinase), changed the treatment pattern of non-small cell lung cancer (NSCLC). Studies have shown that only the EGFR sensitive mutation population can benefit from the detection of EGFR mutation. The main method for detecting EGFR mutation is to analyze the DNA sequence of EGFR. Samples can be obtained from lung cancer, pleural effusion tumor cells, circulating tumor cells. The biggest disadvantage of free DNA in peripheral blood is that it can not analyze the heterogeneity of EGFR mutation. However, with the development of molecular imaging, computed tomographic tomography (PET) -computed tomography CT (computed tomographic CT) targeted EGFR-targeted molecular probes have been developed, which is still not mature for the detection and analysis of mutations at protein level, but with the development of molecular imaging, the molecular probe was developed based on positron emission tomography (PET) and computed tomography (CT). It is possible to detect EGFR mutation status in lung cancer tissue in vivo and to detect the heterogeneity of EGFR mutation. In this paper, the research results and progress of molecular probes targeting EGFR mutations are reviewed.
【作者单位】：中南大学湘雅二医院肿瘤中心;中国人民解放军总医院核医学科;中南大学湘雅三医院医学实验中心;
【基金】：湖南省科技计划项目应用基础研究重点项目基金(No.2016JC2064)资助~~
【分类号】：R734.2

【相似文献】